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Abstract
Current guidelines on the management of patients with neovascular age-related macular degeneration (nAMD) lack clear
recommendations on the interpretation of fluid as seen on optical coherence tomography (OCT) imaging and the incorporation of
this information into an ongoing disease treatment strategy. Our objective was to review current guidelines and scientific
evidence on the role of fluid as a biomarker in the management of nAMD, and develop a clinically oriented, practical algorithm
for diagnosis and management based on a consensus of expert European retinal specialists. PubMed was searched for articles
published since 2006 relating to the role of fluid in nAMD. A total of 654 publications were screened for relevance and 66
publications were included for review. Of these, 14 were treatment guidelines, consensus statements and systematic reviews or
meta-analyses, in which OCT was consistently recommended as an important tool in the initial diagnosis and ongoing
management of nAMD. However, few guidelines distinguished between types of fluid when providing recommendations. A
total of 52 publications reported primary evidence from clinical trials, studies, and chart reviews. Observations from these were
sometimes inconsistent, but trends were observed with regard to features reported as being predictive of visual outcomes. Based
on these findings, diagnostic recommendations and a treatment algorithm based on a treat-and-extend (T&E) regimen were
developed. These provide guidance on the diagnosis of nAMD as well as a simple treatment pathway based on the T&E
regimen, with treatment decisions made according to the observations of fluid as a critical biomarker for disease activity.
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Since the widespread introduction of optical coherence
tomography (OCT) for the visualisation of the back of the
eye in patients with eye diseases such as neovascular age-
related macular degeneration (nAMD), the evaluation of
lesion morphology using OCT has become a key part of the
clinical decision-making pathway [1]. Markers for disease
activity based on OCT, including intraretinal and subretinal
as well as subretinal pigment epithelium (RPE) fluid, are
crucial for guiding management and treatment frequency of
nAMD patients.
Recent advances in OCT technology have led to
increases in speed and resolution that permit the detection of
small structural changes to the retinal layers [2]. However,
the interpretation of OCT images can be complex and
challenging. Although this is an area of considerable sci-
entific interest and extensive literature exists which attempts
to evaluate the influence of different types of fluid on out-
comes in nAMD, current guidelines may be lacking or open
to misinterpretation when it comes to translating the diag-
nostic findings from an OCT into an ongoing disease
treatment strategy. Clear treatment recommendations that
consider both clinical and real-world considerations are
therefore required.
The objective of this consensus article is to review the
current guidelines and scientific evidence on the role of
fluid as a biomarker in the management of nAMD and
provide clinically useful recommendations based on a
consensus of expert European retinal specialists. Further-
more, limitations of current literature and areas of further
research are also highlighted.
Methods
A preliminary review of the literature on the role of fluid
in the management of nAMD was performed by Novartis
in preparation for a roundtable discussion with European
retinal specialists (consensus panel, consisting of LK,
MP, RDM, FGH, MRM, MN, FR, RS, SJT, JZV and
SAZ), held in Zurich, Switzerland (19 July 2019). During
this initial meeting, the available scientific evidence—
and the lack of it—were discussed, resulting in the pro-
posal from the consensus panel to develop simplified
treatment recommendations in nAMD. The literature
review was subsequently repeated with revised search
parameters and the updated results were subject to further
review by the consensus panel during the development of
the treatment recommendations, ensuring scientific
rigour and unbiased interpretation. Novartis was not
involved in the interpretation of the literature search
results or the development of the treatment
recommendations.
The repeated literature search of PubMed was performed
according to the predefined search parameters shown in
Table 1, with other relevant publications included from
information sources such as recent congress presentations
and educational resources. The resulting publications were
screened by title and abstract for relevance and according to
the following exclusion criteria: case reports and studies
with fewer than 50 patients; opinion pieces other than
expert consensus recommendations and guidelines; non-
English language publications; and publication date prior to
2006. The scientific evidence that was retrieved by the
search was tabulated and graded according to recent Eur-
opean guidance [3].
The evidence was discussed by the consensus panel and
used, along with their expert opinion and experience, to
inform the development of a consensus management algo-
rithm for patients with nAMD based primarily on obser-
vations of fluid from OCT monitoring. The nAMD-specific
terminology used within this article follows recent con-
sensus nomenclature for reporting nAMD data [4]. The term
intraretinal fluid (IRF) is used throughout the document to
standardise the different terms used to describe the presence
of fluid within the retina including intraretinal cystoid
oedema, intraretinal cysts, cystoid oedema, cystoid macular
oedema and retinal fluid.
Table 1 Search parameters.
Parameters
(“age-related macular degeneration”[All Fields] OR AMD[All
Fields]) AND fluid[All Fields]
AND date limits: 2006–2019




• Association or correlation or predictor or biomarker and visual
acuity or visual function or vision
• Association or correlation or predictor or biomarker and disease
progression








AMD age-related macular degeneration, CRT central retinal thickness,
CST central subfield thickness.
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Results
The literature review was performed on September 25, 2019
(Fig. 1). After screening of 654 publications and excluding
those that were not relevant or were outside the scope of the
review, a total of 66 publications were included. Of these,
14 publications were treatment guidelines, consensus
statements and systematic reviews or meta-analyses, while
52 publications reported primary evidence from clinical
trials, studies, and chart reviews.
Treatment guidelines
Six treatment guidelines from institutions in Europe and the
USA were retrieved by the search. In the Royal College of
Ophthalmologists’ (RCOphth) guidance on the use of
ranibizumab in nAMD from 2009, new subretinal fluid
(SRF) with or without haemorrhage is included as one
criteria for treatment initiation, while their definition of
disease activity for continuation of treatment includes IRF,
SRF, sub-RPE fluid and haemorrhage [5]. In later guide-
lines on AMD from 2013, the RCOphth provided similar
recommendations relating to fluid [6]. These latter guide-
lines have since been archived following the publication of
the National Institute for Health and Care Excellence
(NICE) guidelines on age-related macular degeneration
(AMD) in January 2018. In these, NICE states that OCT
should be offered to individuals with suspected active
nAMD, or for ongoing monitoring of patients with active
nAMD. No specific guidance is given with regard to fluid
and treatment or management of the condition [7].
Few guidelines distinguished between types of fluid
when providing recommendations, with the same retreat-
ment approach generally recommended regardless of the
type and location of fluid observed. One of the few that
made a distinction between fluid types was the 2014
EURETINA guideline on nAMD, which advised that IRF,
SRF and RPE detachments are important signs of neovas-
cular activity independent of central retinal thickness
(CRT), and that a ‘zero tolerance’ approach to OCT criteria
is justified given the rapid progression of exudative features
and progressive loss of vision when initiation of treatment is
delayed in nAMD. However, longstanding persistent IRF
should be considered a sign of irreversible retinal damage
which should not prompt continued retreatment. Performing
OCT was recommended as the most useful tool for evalu-
ating morphological changes since it provides the most
accurate reflection of the recurrence of disease activity.
Qualitative morphology-based OCT data were considered to
be more sensitive than current quantitative measurements
such as CRT for detecting choroidal neovascularisation
(now termed macular neovascularisation [MNV])
activity [8].
In the American Academy of Ophthalmology preferred
practice pattern for AMD from 2015, there is no specific
mention of how to interpret retinal fluid in diagnosis or
follow-up, other than a statement that as-needed treatment
should be based on the presence or absence of SRF or IRF
[9]. Finally, recommendations on outcome measures for
macular degeneration provided by the International Con-
sortium for Health Outcomes Measurement and a group of
experts in 2016 advised that the presence of IRF, SRF or
haemorrhage attributable to neovascular lesion activity (as
determined by the treating ophthalmologist) should be
assessed at each clinic visit [10].
Consensus statements
A number of expert consensus statements have provided
guidance on the management of nAMD including recom-
mendations relating to fluid and other anatomical para-
meters visualised using OCT. These are broadly consistent
but differ in the detail of interpreting the various morpho-
logical features.
In 2011, a group of 22 European experts provided con-
sensus recommendations for anti-vascular endothelial
growth factor (VEGF) management of nAMD based on
morphological criteria. Suggested retreatment criteria under
a pro-re-nata (PRN) regimen included IRF, SRF, diffuse
foveal thickening and expanding serous pigment epithelium
detachment (PED). Criteria for delaying treatment included
the absence of the above criteria, stable serous PED and
stable IRF that has not responded to three intravitreal
injections [11]. Notably, at the time of these recommenda-
tions, retreatment criteria were based on the assessment of a
single transfoveal OCT image [11]. A committee of UK-
based retinal experts published a consensus paper defining
response to anti-VEGF therapy in nAMD in 2015.
They noted that there is often little correlation between
Fig. 1 Literature review flow diagram. Sixty-six eligible publica-
tions were selected for inclusion.
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morphological and functional responses to anti-VEGF
treatments, and so recommended a combination of mor-
phology and function as the means of determining treatment
response, with the morphology component defined as IRF,
SRF and retinal thickening [12].
In a 2017 expert round-table consensus on the treatment
of nAMD with aflibercept in the second year of therapy,
fluid was a recommended consideration when making the
decision to maintain a fixed regimen or move to a treat-and-
extend (T&E) dosing schedule. The criteria for not
extending the treatment interval included persistent macular
fluid with stable vision, recurrent fluid, and decrease in
vision in the presence of fluid. Extension of intervals
between treatments was recommended for eyes with no
macular fluid and stable vision [13].
A recent Greek consensus statement on the management
of nAMD recognised the importance of morphological
signs of disease activity observed using OCT, which the
authors note correspond to early signs of recurrence prior to
measurable loss of VA. The main anatomic parameters to be
taken into consideration according to their recommenda-
tions were CRT, SRF, IRF, anatomy of the outer retinal
layers and PED [14].
Systematic reviews
Four systematic reviews were included in the literature
review. The earliest of these was a systematic review on
OCT for diagnosis, monitoring and guiding treatment for
nAMD by Mowatt and colleagues from 2014, which con-
cluded that strategies involving OCT alone for diagnosis
and/or monitoring were unlikely to be cost-effective, while
those that also included fluorescein angiography (FA) and
other imaging techniques were more likely to be considered
cost-effective. However, many of the studies included in
this review used older, time-domain OCT technology which
may have compromised the specificity of the technique in
terms of detecting active nAMD. For the purposes of this
review, nAMD was considered to be active or inactive, with
no specific discussion relating to fluid [15]. In contrast, a
review by Schmid-Erfurth and Waldstein from 2016 pro-
vided detailed information on imaging biomarkers in
nAMD. The authors concluded that CRT is an inferior
prognostic biomarker for guiding retreatment compared
with localisation of fluid in different compartments,
including IRF and SRF. IRF at baseline is negatively
associated with VA, while SRF at baseline (i.e., in naive
patients) is associated with superior visual benefits and a
lower rate of progression towards atrophy. The finding of
SRF is associated with all lesion types and is typically the
first exudative sign in Type 1 lesions. RPE detachment was
identified as unresponsive to therapy and responsible for
visual decline [16]. A later systematic review on OCT in the
management of AMD by the same group provided a
detailed discussion of morphological features indicative of
disease activity, but was accompanied by no clear guidance
for treatment [17].
A systematic review of the evidence on using morpho-
logical predictors to modify treatment protocols in nAMD
was performed by Ashraf et al. [18], finding that a good
response in terms of reduction in SRF at 12 weeks predicted
good visual outcomes, but that patients with PED and IRF
achieved smaller visual gains and their treatment intervals
should be extended with caution.
Primary evidence
The 52 primary publications of clinical trials and studies
retrieved by the literature search were reviewed for relevant
detail on the role or impact of fluid in nAMD. Of these, one
publication was the primary output of a randomised con-
trolled trial (RCT) [19], 21 publications were post-hoc ana-
lyses, exploratory analyses and prospective cohort studies
related to several medium and large RCTs (ABC trial [20],
PIER [21], CATT [22–27], MONT BLANC [28], EXCITE
[29, 30], GEFAL [31], VIEW 1 and 2 [32–36] and HARBOR
[37–39]), 5 publications described prospective, non-
randomised studies, and the remaining 25 publications were
retrospective chart reviews and case series. Table 2 provides a
summary of the studies and their findings, while Table 3
compares features of several of the key RCTs of anti-VEGF
therapy in nAMD, including the retreatment criteria applied to
the flexible treatment arms or phases of these trials.
Several studies reported that the presence of baseline SRF
predicts a good response to anti-VEGF treatment, resulting in
favourable visual outcomes [25, 26, 37, 40–42]. Evidence
also suggests that small amounts (defined by the FLUID study
as less than 200 µm) of residual stable SRF can be tolerated
without impact on VA [19, 43]. However, one study reported
that recurrent SRF is predictive of a poor functional prognosis
[44]. A substantial number of studies reported consistent
findings indicating that the presence of IRF (at baseline or
recurring) is predictive of a poor prognosis
[22, 23, 25, 27, 31, 41, 42, 44–52]. New or growing sub-RPE
fluid is reported in one study as being an early sign of con-
version to nAMD [53], while another study found an increase
in sub-RPE fluid to be a marker for progressive disease
activity which warrants treatment [32]. While this could be
considered a useful predictive biomarker if observed over
time, it should be noted that the presence of sub-RPE fluid in
a single OCT scan without the presence of SRF and IRF is not
necessarily indicative of disease progression.
Several publications found the type or spatial localisation
of fluid to have limited prognostic value in terms of pre-
dicting response to anti-VEGF therapy [33, 38, 54, 55]. In
the VIEW studies, a post-hoc analysis reported that BCVA
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change from baseline to week 52 was independent of the
presence or absence of fluid at week 12 [34]. However,
contrasting evidence from the PIER study suggests that an
absence of fluid on OCT is predictive of greater BCVA
gains with anti-VEGF treatment [21].
A significant number of studies found either abnormally
thick or abnormally thin retinas to be associated with poor
outcomes [20, 22, 25, 27, 31, 49, 52, 56, 57]. Reduced
retinal thickness has been associated with decreased retinal
sensitivity [58], and an increased total volume of subretinal
tissue has been correlated with decreased VA or contrast
sensitivity [20, 57]. In a retrospective study of patients
initially treated with ranibizumab and then switched to
aflibercept, subfoveal thickening and increased retinal cen-
tral subfield thickness were reported to be predictive of poor
prognosis in non-treatment naive patients [49]. In contrast,
however, two studies reported that change in retinal thick-
ness is not predictive of treatment outcomes [54, 59].
Finally, a small number of publications commented on
correlations between fluid and required anti-VEGF injection
frequency. Two publications reported that a thicker retina at
baseline was associated with greater injection requirements
[37, 60], while another stated that the presence of SRF was
predictive of the need for a higher injection frequency [28]. A
post-hoc analysis of the VIEW studies reported that the
absence of retinal fluid at 1 year was predictive of the ability to
achieve extended treatment intervals of at least 12 weeks [36].
Algorithm for the management of nAMD
Based on the available scientific evidence described above
and the experience of the consensus panel, an algorithm for
the most optimal management of patients with nAMD based
on fluid observed using OCT and other imaging technolo-
gies is recommended, irrespective of country guidance and
resource constraints, as shown in Fig. 2.
Aim to iniate treatment as soon as possible following diagnosis 
(usually within 1 week according to most European recommendaons)
Signs of disease acvity present?
Yes No
If 3 consecuve visits occur with insufficient 
anatomical treatment response
If nAMD diagnosis confirmed to be correct
Connue to treat
If there is sll insufficient anatomical 
response aer at least 2–3 addional 
injecons, consider switching to an 
alternave an-VEGF agent  
When switching to a different agent, this 
can be done with or without an iniaon 
phase based on the type of lesion, level of 
disease acvity and paent characteriscs, 
according to the judgment of the clinician
Check diagnosis, performing addional 
imaging if needed and considering potenal 
misdiagnoses (see Table 4)
Reducon of treatment interval by 
2–4 weeks to a minimum of 4 weeks
Confirmed diagnosis of nAMD
Iniate an-VEGF treatment
Iniaon phase of at least 2 injecons at monthly intervals 
Duraon of iniaon phase should be individualised 
based on inial paent response
An-VEGF treatment according to T&E regimen
Proacve treatment at each clinic visit
Extension of treatment interval by 2–4 
weeks to a maximum of 16 weeks
If a fixed interval can be found at which the 
paent is stable, this should be maintained. 
Current evidence does not support stopping 
treatment, but connued long-term 
treatment may not be appropriate or 
beneficial in paents with low vision with 
fibrosis, extensive subrenal haemorrhage, 
ELM disrupon, ellipsoid zone disrupon and 
RPE (central) atrophy
Assess disease acvity using OCT 
Signs of disease acvity include:
• New sub- or intrarenal haemorrhage 
• Persistent or increase in diffuse renal 
thickening (IRF)
• New SRF or an increase in SRF
• New/increased PED or sub-RPE fluid
• Subrenal hyperreflecve material represenng a 
neovascular membrane
Paent with suspected nAMD




• Intrarenal neovascularizaon (type 3 MNV)
• Subrenal hyperreflecve material (type 2 MNV or 
mixed type 1 and type 2 MNV)
Stereoscopic biomicroscopic examinaon or fundus 
photography to visualise supporng clinical signs of nAMD
e.g. haemorrhage, hard exudates, macular edema, subrenal 
fibrosis, pigment epithelial elevaon
OCT-A (if available) to visualise 
neovascular complex 
If neovascular complex not 
visible on OCT-A or if OCT-A 
not available, consider FA to 
visualise leakage 
If there is suspicion of PCV, 
consider ICGA
One or more parameters present?
Yes No
Consider differenal diagnoses 
(see Table 4)
Other imaging modalies as required in order to confirm 
diagnosis based on observaons
Clinical decision on nAMD diagnosis
a b
Fig. 2 Algorithm for the management of nAMD: recommendations by the consensus panel. a Diagnosis. b Management according to a treat-
and-extend regimen. anti-VEGF anti-vascular endothelial growth factor, ELM external limiting membrane, ICGA indocyanine green angiography,
IRF intraretinal fluid, FA fluorescein angiography, MNV macular neovascularisation, nAMD neovascular age-related macular degeneration, OCT
optical coherence tomography, OCT-A optical coherence tomography angiography, PCV polypoidal choroidal vasculopathy, PED pigment
epithelial detachment, RPE retinal pigment epithelium, SRF subretinal fluid, T&E treat and extend.
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Diagnosis and diagnostic techniques
The consensus panel agreed that morphological parameters
observed on OCT are the most important criteria in routine
clinical practice for the diagnosis of nAMD. The whole
stack of images should be used, to give as full a picture as
possible. The characteristic features considered to be indi-
cative of nAMD are SRF, IRF and fibrovascular PED
(Fig. 2a). OCT can permit differentiation of the type of
MNV and location of fluid, but at baseline many cases also
require additional information from other imaging mod-
alities in order to confirm the diagnosis. If available, OCT-
angiography (OCT-A) is considered to be valuable in order
to visualise the neovascular complex. If OCT-A is not
available, FA can be used to visualise leakage from the
lesion, but is otherwise no longer judged to be a mandatory
technique for nAMD diagnosis in all AMD cases. However,
clinical signs visualised using biomicroscopy or fundus
photography/examination are still considered useful to
support the diagnosis. In cases where PCV or type 3 MNV
is suspected, ICGA and OCT-A are recommended to con-
firm this diagnosis. In addition to the morphological and
clinical signs of nAMD, patient age over 50 years is an
important criterion for a diagnosis of nAMD.
A range of conditions have the potential to masquerade
as nAMD. Table 4 lists a number of these potential mis-
diagnoses or pitfalls. Of these, the most common are adult-
onset foveomacular vitelliform dystrophy and central serous
chorioretinopathy. When examining a patient with putative
nAMD, the clinician should be aware of and exclude these
common differential diagnoses.
Treatment
The agreement of the consensus panel was that, regardless
of the anti-VEGF agent used, T&E is the recommended
regimen for the management of nAMD because it provides
comparable clinical outcomes to fixed monthly or
bimonthly injections with a reduction in injection burden
compared with fixed dosing [61, 62]. T&E also provides a
reduction in the number of clinic visits compared with PRN
with monthly monitoring, provided that a one-step visit
(with follow-up and injection on the same day) is possible.
The potential for development of atrophy with intensive
anti-VEGF therapy was considered to be less of a concern
than the likelihood of visual acuity loss resulting from
undertreatment, since a link between the number of injec-
tions and the risk of developing atrophy has never been
proven. On the contrary, current evidence suggests that anti-
VEGF therapy is not a significant risk factor for the
development of macular atrophy. For example, a post-hoc
analysis of data from the HARBOR study reported no
association of number of ranibizumab injections with
macular atrophy development, and no significant associa-
tion between regimen (monthly vs PRN treatment) and
macular atrophy development [63]. Another post-hoc ana-
lysis of data from the same trial using Classification of
Atrophy Meetings (CAM) group atrophy criteria found no
differences in the incidence or progression rates of new
macular atrophy among study arms, anti-VEGF doses, or
treatment regimens [64]. However, there is evidence that
neovascularisation type may be associated with the devel-
opment of atrophy, with patients with type 1 MNV at
baseline less likely to develop atrophy than eyes with other
forms of MNV [65]. In contrast, patients with type 3 MNV
Table 4 Potential misdiagnoses for nAMD.
Category Condition




Macular telangiectasia type 1
MNV secondary to Sorsby fundus
dystrophy
MNV secondary to Stargardt disease
Trauma and infection MNV secondary to presumed ocular
histoplasmosis syndrome
MNV secondary to choroidal rupture
MNV secondary to trauma/laser pointers
Chorioretinal uveitis syndromes Inflammatory MNV
Chorioretinitis







Non-neovascular AMD, e.g., avascular
PEDs with or without pockets of SRF
Neurodegenerative conditions Macular telangiectasia type 2





MNV secondary to previous laser
photocoagulation in cases with
concomitant DMO
MNV secondary to angioid streaks
Degenerative structural features
that mimic neovascular activity
Outer retinal tubulation





AMD age-related macular degeneration, DME diabetic macular
oedema, MNV macular neovascularization, nAMD neovascular age-
related macular degeneration, PED pigment epithelial detachment,
SRF subretinal fluid.
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and subretinal drusenoid deposits at baseline have a high
risk of atrophy development [66].
Treatment with anti-VEGF therapy should be initiated as
soon as possible once the diagnosis of nAMD is made.
Guidelines and institutional guidance vary throughout
Europe, with most recommendations advising that treatment
should take place within 1 week of referral. The NICE
guidelines mandate treatment within 14 days of referral, but
specify that referral should take place within 1 working day
of diagnosis [7]. Treatment should begin with an initiation
phase before the clinician considers extending the treatment
interval (Fig. 2b). This usually consists of three injections
given at monthly intervals, but in some circumstances (as
seen in real-world datasets [67]) could entail just two
injections depending on the response of the individual
patient. After that, the patient is evaluated for extension
criteria, and the treatment interval can be increased by
2–4 weeks at a time.
Treatment should be given proactively at each visit—a
key aspect of T&E treatment design. The decision on
whether the treatment interval should be extended, retained,
or reduced is also made at each visit, and is based on disease
activity as assessed using OCT. The signs of disease activity
that should trigger a reduction in treatment interval include
new haemorrhage beneath or within the retina, new or
persistent IRF, new or increased SRF, increased size of
PED, or the presence of subretinal hyperreflective material
which would indicate the presence of a neovascular
membrane. If one or more of these signs are present,
the treatment interval should be reduced by 2–4 weeks, to
a minimum of 4 weeks. However, in a minority of cases
with recurrent disease activity, the clinician may feel
that an extension or reduction of 1 week might be more
appropriate.
If disease activity is observed at three consecutive visits,
with no sign of anatomical and/or functional improvement,
the clinician should consider whether the initial diagnosis of
nAMD was correct, using additional imaging modalities to
provide more information if necessary. It might be possible
that the patient is not a non-responder but has instead been
misdiagnosed for nAMD. If further investigation confirms
the original diagnosis, then the consensus panel recom-
mends that treatment should be continued for at least 2 to 3
additional injections at the minimum interval permitted by
the product label before a switch to an alternative anti-
VEGF therapy is considered. If a patient is switched to a
different anti-VEGF therapy due to lack of efficacy, this
should be done with a new initiation phase. However, a
simulated switching study has suggested that continuation
of initial therapy will, in many cases, result in a gradual
improvement or stabilisation similar to that commonly
reported following a therapy switch in published anti-VEGF
switching studies [68].
If there is no evidence of disease activity at the treatment
visit, the clinician may consider extending the treatment
interval by 2–4 weeks [69], to a maximum of 16 weeks (or
potentially more with longer-acting anti-VEGF agents),
however, there will be a higher risk of recurrence [67]. If a
patient reaches stability at a particular treatment interval,
this should be maintained over the long term if feasible. If
the treatment interval is alternately being extended and
reduced at each visit, the clinician can consider that the
shorter of the two intervals is the more appropriate one for
the patient and maintain this interval for a period of time
before re-evaluating the patient’s treatment needs in due
course. There is currently no evidence to support stopping
anti-VEGF treatment in patients with stable disease, as
disease activity will very likely recur, but the clinician may
consider that continued long-term anti-VEGF therapy may
not be appropriate or beneficial in patients with low vision
who have fibrosis, extensive subretinal haemorrhage, sub-
foveal disruption of the external limiting membrane or the
ellipsoid zone or central atrophy of the RPE.
Discussion and conclusion
The aim of this consensus article is to consider the evidence
and guidance currently available in the scientific literature
on the role of fluid in the management of nAMD and pro-
vide recommendations as to how it might be integrated into
everyday clinical practice based on the opinion of a panel of
expert retinal specialists. Our understanding of the role of
fluid in nAMD is still evolving and in some instances the
observations reported in the scientific literature are con-
flicting and confusing. The treatment recommendations
provided here are based on our best interpretation of the
available data at this time. The resulting algorithm for the
diagnosis and management of nAMD provides clear gui-
dance on recommended diagnostic tools and what they can
be used to identify, as well as a simple treatment pathway
based on the T&E regimen. It aims to provide the best
possible visual outcomes for patients whilst acknowledging
the restrictions that are inevitably encountered in real-world
clinical practice. Treatment decisions are made according to
observations of fluid as a biomarker for disease activity in
nAMD. This publication is not an exhaustive review of the
T&E regimen, which varies in detail between publications,
but provides a recommended version of the T&E regimen
based on the combined clinical experience of the consensus
panel, and guided by fluid.
The detection of fluid on OCT is generally used to imply
the presence of a VEGF-related leak that the clinician could
expect to respond to anti-VEGF therapy. However, in some
cases, the fluid spaces seen on OCT may actually be
structural changes such as outer retinal tubulation that are
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not responsive to anti-VEGF treatment [70]. Where this is
suspected, strategies to confirm that fluid is VEGF-driven
include monitoring patients shortly after treatment (e.g.,
2 weeks after injection) to check for a short-lived treatment
response, checking for leakage from the lesion using FA,
and assessing whether the putative fluid worsens with an
extended treatment interval.
There are a number of limitations associated with this
review and consensus. The scientific evidence reviewed
here is limited in that the literature search retrieved only one
level 1 evidence trial (the FLUID study) that specifically
aimed to evaluate the impact of fluid in the management of
nAMD [19]. Even this study had limitations in terms of
determining the effect of treating fluid versus leaving it
untreated since patients were treated at every visit in both
treatment arms. Interestingly, both the arms where SRF was
more tolerated and the arm where it was treated more
aggressively had relatively high and nearly identical injec-
tion frequencies (means of 15.8 and 17 injections over 2
years). The remainder of the evidence comes from a number
of RCTs in which the effect of fluid on treatment outcomes
was an observational, secondary or exploratory outcome or
the subject of a post-hoc analysis, or in the form of lower
level evidence from prospective but uncontrolled trials and
retrospective chart reviews. For the purposes of this review,
all publications that met the literature review inclusion
criteria have been considered, regardless of the level of
evidence.
The imaging technologies used in the studies included
here have not remained constant over the time span of the
literature review. OCT has evolved from time domain to
spectral domain modalities, meaning that the observations
reported by the earliest publications returned by the litera-
ture search are not directly comparable to the more recent
publications. Several of the larger RCTs used these older
imaging techniques, which may detract from the relevance
of their findings to current practice. Other measured para-
meters may have also changed over time.
A final limitation of this work is that for the purposes of
providing clear guidance that can be used on a day-to-day
basis by the practising clinician, this review and consensus
focusses only on the role of fluid in nAMD. In addition to
fluid, a range of other morphological features visible on OCT
such as external limiting membrane, ellipsoid zone and RPE
disruption, and the presence of PED and hyperreflective
material have been associated with poor visual acuity out-
comes [23, 24, 27–29, 31, 35, 40, 42, 45, 49–52, 71–75]. A
relationship has also been observed between visual acuity
outcomes and the type of neovascularisation. At baseline, type
1 MNV is a predictor of better visual acuity following anti-
VEGF treatment compared with other lesion types, and eyes
with this type of lesion often have SRF [76]. These associated
morphological findings are also important features with
prognostic value which can co-exist with fluid. However,
given the difficulties in visualising, identifying and con-
sistently assessing some of these other features, we are of the
opinion that fluid is the most practical and useful biomarker of
VEGF upregulation and MNV activity in nAMD.
In conclusion, gaps exist in the scientific literature on the
role of fluid in the management of patients with nAMD. The
limitations described here highlight the real need for
appropriately designed and executed studies to provide a
standardised and detailed understanding of the appearance
of different specific fluid manifestations and their con-
sequences on clinical outcomes. However, it is quite clear
that the primary treatment goal is to eliminate fluid as
effectively as possible. Future research into this important
area could provide valuable insights to direct optimal
treatment to achieve this. In the meantime, following expert
consideration of the evidence available, we recommend that
patients with nAMD receive anti-VEGF therapy according
to a T&E regimen with treatment intervals determined
according to fluid-based disease activity parameters
observed using OCT.
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Compliance with ethical standards
Conflict of interest LK is a consultant for Allergan, Alimera, Bayer,
Horus, Krys, Novartis, Roche and Théa. MP is a consultant for
Allergan, Novartis, Bayer, and Zeiss outside the submitted work. AC
and RKV are full time employees and shareholders at Novartis Pharma
A.G. RDM is a consultant for Heidelberg Engineering, Novartis and
Allergan, and receives research support from Genentech/Roche. FGH
is a consultant for and/or has received funding for research from:
Acucela, Allergan, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/For-
mycon, CenterVue, Ellex, Roche/Genentech, Geuder, Grayburg
Vision, Heidelberg Engineering, Kanghong, LinBioscience, Night-
StarX, Novartis, Optos, Pixium Vision, Oxurion, Stealth BioTher-
apeutic, and Zeiss. MRM is a consultant for Zeiss, Lumithera, Bayer,
Novartis and Oculis. MN is a consultant for and/or has received
L. Kodjikian et al.
funding for research from: Allergan, Bayer, Novartis and Sifi. FR is a
consultant for Allergan, Alimera, Bayer, MS&D, Novartis and Roche.
RS is a consultant for Allergan, Alimera, Bayer, Novartis and Théa.
SJT is a consultant for Bayer and Novartis, received grant support
from Bayer, Novartis and Heidelberg Engineering, and is involved in
research for Allergan, Roche, Bayer, Novartis and Boehringer-
Ingelheim. JZV is a consultant for Alcon, Alimera Sciences, Aller-
gan, Bayer, Novartis and Roche, has received grants from Allergan
and Novartis and is a lecturer for Bausch and Lomb, DORC, Topcon
and Zeiss. SAZ is a consultant for Allergan, Bayer HealthCare,
Novartis and Roche and has received grant support from Bayer
HealthCare and Novartis.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Staurenghi G, Sadda S, Chakravarthy U, Spaide RF. International
Nomenclature for Optical Coherence Tomography Panel. Pro-
posed lexicon for anatomic landmarks in normal posterior seg-
ment spectral-domain optical coherence tomography: the IN*OCT
consensus. Ophthalmology. 2014;121:1572–8.
2. Li Y, Xia X, Paulus YM. Advances in retinal optical imaging.
Photonics. 2018;5:9.
3. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-
Garcher C, Dimitrakos SA 2nd, et al. Evolving European guidance
on the medical management of neovascular age related macular
degeneration. Br J Ophthalmol. 2006;90:1188–96.
4. Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi
G, et al. Consensus nomenclature for reporting neovascular age-
related macular degeneration data: consensus on neovascular age-
related macular degeneration nomenclature study group. Oph-
thalmology. 2020;127:616–36.
5. Amoaku W. Ranibizumab: the clinician’s guide to commencing,
continuing, and discontinuing treatment. Eye. 2009;23:2140–2.
6. Chakravarthy U, Williams M. AMD Guidelines Group. The Royal
College of Ophthalmologists guidelines on AMD: executive
summary. Eye. 2013;27:1429–31.
7. National Institute for Health and Care Excellence. Age-related
macular degeneration. NICE guidelines [NG82]. 2018.
https://www.nice.org.uk/guidance/ng82. Accessed September
2019.
8. Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied
E, Schlingemann R, et al. Guidelines for the management of
neovascular age-related macular degeneration by the European
Society of Retina Specialists (EURETINA). Br J Ophthalmol.
2014;98:1144–67.
9. American Academy of Ophthalmology. Age-related macular
degeneration preferred practice pattern. 2015. https://www.aao.
org/preferred-practice-pattern/age-related-macular-degeneration-
ppp-2015. Accessed September 2019.
10. Rodrigues IA, Sprinkhuizen SM, Barthelmes D, Blumenkranz M,
Cheung G, Haller J, et al. Defining a minimum set of standardized
patient-centered outcome measures for macular degeneration. Am
J Ophthalmol. 2016;168:1–12.
11. Pauleikhoff D, Kirchhof B. Retreatment criteria in anti-VEGF
therapy of exudative AMD: critical analysis of present regimes
and new morphological definition of “lesion activity”. Graefes
Arch Clin Exp Ophthalmol. 2011;249:631–2.
12. Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F,
Gibson J, et al. Defining response to anti-VEGF therapies in
neovascular AMD. Eye. 2015;29:721–31.
13. Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale
RP, et al. Aflibercept treatment for neovascular AMD beyond the
first year: consensus recommendations by a UK expert roundtable
panel, 2017 update. Clin Ophthalmol. 2017;11:1957–66.
14. Androudi S, Dastiridou A, Pharmakakis N, Stefaniotou M,
Kalogeropoulos C, Symeonidis C, et al. Guidelines for the man-
agement of wet age-related macular degeneration: recommenda-
tions from a panel of Greek experts. Adv Ther. 2016;33:715–26.
15. Mowatt G, Hernandez R, Castillo M, Lois N, Elders A, Fraser C,
et al. Optical coherence tomography for the diagnosis, monitoring
and guiding of treatment for neovascular age-related macular
degeneration: a systematic review and economic evaluation.
Health Technol Assess. 2014;18:1–254.
16. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging
biomarkers in neovascular age-related macular degeneration. Prog
Retin Eye Res. 2016;50:1–24.
17. Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunovic H. A
view of the current and future role of optical coherence tomo-
graphy in the management of age-related macular degeneration.
Eye. 2017;31:26–44.
18. Ashraf M, Souka A, Adelman RA. Age-related macular degen-
eration: using morphological predictors to modify current treat-
ment protocols. Acta Ophthalmol. 2018;96:120–33.
19. Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP,
Arnold JJ, et al. Tolerating subretinal fluid in neovascular age-
related macular degeneration treated with ranibizumab using a
treat-and-extend regimen: FLUID study 24-month results. Oph-
thalmology. 2019;126:723–34.
20. Keane PA, Patel PJ, Ouyang Y, Chen FK, Ikeji F, Walsh AC,
et al. Effects of retinal morphology on contrast sensitivity and
reading ability in neovascular age-related macular degeneration.
Investig Ophthalmol Vis Sci. 2010;51:5431–7.
21. Brown DM, Tuomi L, Shapiro H. Pier Study G. Anatomical
measures as predictors of visual outcomes in ranibizumab-treated
eyes with neovascular age-related macular degeneration. Retina.
2013;33:23–34.
22. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS,
et al. Macular morphology and visual acuity in the comparison of
age-related macular degeneration treatments trials. Ophthalmol-
ogy. 2013;120:1860–70.
23. Ying GS, Kim BJ, Maguire MG, Huang J, Daniel E, Jaffe GJ,
et al. Sustained visual acuity loss in the comparison of age-related
macular degeneration treatments trials. JAMA Ophthalmol.
2014;132:915–21.
24. Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald
JE, et al. Angiographic cystoid macular edema and outcomes in
the comparison of age-related macular degeneration treatments
trials. Ophthalmology. 2016;123:858–64.
25. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying
GS, et al. Macular morphology and visual acuity in the second
Fluid as a critical biomarker in neovascular age-related macular degeneration management
year of the comparison of age-related macular degeneration
treatments trials. Ophthalmology. 2016;123:865–75.
26. Ying GS, Maguire MG, Pan W, Grunwald JE, Daniel E, Jaffe GJ,
et al. Baseline predictors for five-year visual acuity outcomes in
the comparison of AMD treatment trials. Opthalmol Retina.
2018;2:525–30.
27. Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF,
et al. Macular morphology and visual acuity in year five of the
comparison of age-related macular degeneration treatments trials.
Ophthalmology. 2019;126:252–60.
28. Ritter M, Simader C, Bolz M, Deak GG, Mayr-Sponer U, Sayegh
R, et al. Intraretinal cysts are the most relevant prognostic bio-
marker in neovascular age-related macular degeneration inde-
pendent of the therapeutic strategy. Br J Ophthalmol.
2014;98:1629–35.
29. Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz
I, et al. Morphologic parameters relevant for visual outcome
during anti-angiogenic therapy of neovascular age-related macular
degeneration. Ophthalmology. 2014;121:1237–45.
30. Waldstein SM, Wright J, Warburton J, Margaron P, Simader C,
Schmidt-Erfurth U. Predictive value of retinal morphology
for visual acuity outcomes of different ranibizumab treatment
regimens for neovascular AMD. Ophthalmology. 2016;
123:60–69.
31. Kodjikian L, Decullier E, Souied EH, Roux A, Aulagner G, Huot
L, et al. Predictors of one-year visual outcomes after anti-vascular
endothelial growth factor treatment for neovascular age-related
macular degeneration. Retina. 2018;38:1492–9.
32. Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader
C. Pigment epithelial detachment followed by retinal cystoid
degeneration leads to vision loss in treatment of neovascular age-
related macular degeneration. Ophthalmology. 2015;122:822–32.
33. Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R,
et al. Differential response to anti-VEGF regimens in age-related
macular degeneration patients with early persistent retinal fluid.
Ophthalmology. 2016;123:1856–64.
34. Moshfeghi DM, Hariprasad SM, Marx JL, Thompson D, Soo Y,
Gibson A, et al. Effect of fluid status at week 12 on visual and
anatomic outcomes at week 52 in the VIEW 1 and 2 trials.
Ophthalmic Surg Lasers Imaging. Retina. 2016;47:238–44.
35. Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P,
Jaffe GJ, et al. Morphology and visual acuity in aflibercept and
ranibizumab therapy for neovascular age-related macular degen-
eration in the VIEW trials. Ophthalmology. 2016;123:1521–9.
36. Khurana RN, Rahimy E, Joseph WA, Saroj N, Gibson A, Vitti R,
et al. Extended (every 12 weeks or longer) dosing interval with
intravitreal aflibercept and ranibizumab in neovascular age-related
macular degeneration: post hoc analysis of VIEW trials. Am J
Ophthalmol. 2019;200:161–8.
37. Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z. Baseline
predictors of 12-month treatment response to ranibizumab in
patients with wet age-related macular degeneration. Am J Oph-
thalmol. 2015;160:1014–23. e1012.
38. Schmidt-Erfurth U, Bogunovic H, Sadeghipour A, Schlegl T,
Langs G, Gerendas BS, et al. Machine learning to analyze the
prognostic value of current imaging biomarkers in neovascular
age-related macular degeneration. Ophthalmol Retina. 2018;2:
24–30.
39. Hu X, Waldstein SM, Klimscha S, Sadeghipour A, Bogunovic H,
Gerendas BS, et al. Morphological and functional characteristics
at the onset of exudative conversion in age-related macular
degeneration. Retina. 2020;40:1070–8.
40. Casalino G, Bandello F, Chakravarthy U. Changes in neovascular
lesion hyperreflectivity after anti-VEGF treatment in age-related
macular degeneration: an integrated multimodal imaging analysis.
Investig Ophthalmol Vis Sci. 2016;57:OCT288–298.
41. Segal O, Barayev E, Nemet AY, Mimouni M. Predicting response
of exudative age-related macular degeneration to bevacizumab
based on spectralis optical coherence tomography. Retina.
2016;36:259–63.
42. Vogel RN, Davis DB, Kimura BH, Rathinavelu S, Graves GS,
Szabo A, et al. Neovascular age-related macular degeneration with
advanced visual loss treated with anti-vascular endothelial growth
factor therapy: Clinical outcome and prognostic indicators. Retina.
2017;37:257–64.
43. Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of
sub-retinal fluid in determining treatment outcomes in patients
with neovascular age-related macular degeneration–a phase IV
randomised clinical trial with ranibizumab: the FLUID study.
BMC Ophthalmol. 2016;16:31.
44. Wickremasinghe SS, Janakan V, Sandhu SS, Amirul-Islam FM,
Abedi F, Guymer RH. Implication of recurrent or retained fluid on
optical coherence tomography for visual acuity during active
treatment of neovascular age-related macular degeneration with a
treat and extend protocol. Retina. 2016;36:1331–9.
45. Dervenis N, Younis S. Macular morphology and response to
ranibizumab treatment in patients with wet age-related macular
degeneration. Clin Ophthalmol. 2016;10:1117–22.
46. Lee H, Jo A, Kim HC. Three-dimensional analysis of morphologic
changes and visual outcomes in neovascular age-related macular
degeneration. Invest Ophthalmol Vis Sci. 2017;58:1337–45.
47. Shin JY, Woo SJ, Ahn J, Park KH. Anti-VEGF-refractory exu-
dative age-related macular degeneration: differential response
according to features on optical coherence tomography. Korean J
Ophthalmol. 2013;27:425–32.
48. Sagiv O, Zloto O, Moroz I, Moisseiev J. Different clinical courses
on long-term follow-up of age-related macular degeneration
patients treated with intravitreal anti-vascular endothelial growth
factor injections. Ophthalmologica. 2017;238:217–25.
49. Chatziralli I, Nicholson L, Vrizidou E, Koutsiouki C, Menon D,
Sergentanis TN, et al. Predictors of outcome in patients with
neovascular age-related macular degeneration switched from
ranibizumab to 8-weekly aflibercept. Ophthalmology. 2016;123:
1762–70.
50. Wickremasinghe SS, Sandhu SS, Busija L, Lim J, Chauhan DS,
Guymer RH. Predictors of AMD treatment response. Ophthal-
mology. 2012;119:2413.e5.
51. Pokroy R, Mimouni M, Barayev E, Segev F, Geffen N, Nemet
AY, et al. Prognostic value of subretinal hyperreflective material
in neovascular age-related macular degeneration treated with
bevacizumab. Retina. 2018;38:1485–91.
52. Segal O, Barayev E, Nemet AY, Geffen N, Vainer I, Mimouni M.
Prognostic value of hyperreflective foci in neovascular age-related
macular degeneration treated with bevacizumab. Retina. 2016;
36:2175–82.
53. Padnick-Silver L, Weinberg AB, Lafranco FP, Macsai MS. Pilot
study for the detection of early exudative age-related macular
degeneration with optical coherence tomography. Retina.
2012;32:1045–56.
54. Fulcher C, Hazel CA, Pacey I, Ali H, Ghanchi FD. Predicting
visual outcomes in patients treated with aflibercept for neovascular
age-related macular degeneration: data from a real-world clinical
setting. Eur J Ophthalmol. 2020;30:543–9.
55. Kolb S, Menghini M, Barthelmes D, Sutter F, Kurz-Levin M. The
predictive value of OCT characteristics for the visual outcome in
neovascular AMD. Klin Monbl Augenheilkd. 2012;229:343–7.
56. Shin JY, Kwon KY, Byeon SH. Association between choroidal
thickness and the response to intravitreal ranibizumab injection in
age-related macular degeneration. Acta Ophthalmol. 2015;93:
524–32.
57. Keane PA, Liakopoulos S, Chang KT, Wang M, Dustin L, Walsh
AC, et al. Relationship between optical coherence tomography
L. Kodjikian et al.
retinal parameters and visual acuity in neovascular age-related
macular degeneration. Ophthalmology. 2008;115:2206–14.
58. Roh M, Lains I, Shin HJ, Park DH, Mach S, Vavvas DG, et al.
Microperimetry in age-related macular degeneration: association
with macular morphology assessed by optical coherence tomo-
graphy. Br J Ophthalmol. 2019;103:1769–76.
59. Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu
T, et al. Subfoveal choroidal thickness during aflibercept therapy
for neovascular age-related macular degeneration: twelve-month
results. Ophthalmology. 2016;123:617–24.
60. Kumar JB, Wai KM, Ehlers JP, Singh RP, Rachitskaya AV.
Subfoveal choroidal thickness as a prognostic factor in exudative
age-related macular degeneration. Br J Ophthalmol. 2019;103:
918–21.
61. Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mones J,
et al. Treat-and-extend versus monthly regimen in neovascular
age-related macular degeneration: results with ranibizumab from
the TREND study. Ophthalmology. 2018;125:57–65.
62. Haga A, Kawaji T, Ideta R, Inomata Y, Tanihara H. Treat-and-
extend versus every-other-month regimens with aflibercept in age-
related macular degeneration. Acta Ophthalmol. 2018;96:
e393–e398.
63. Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular
atrophy in the HARBOR study for neovascular age-related
macular degeneration. Ophthalmology. 2018;125:878–86.
64. Gune S, Abdelfattah NS, Karamat A, Balasubramanian S, Marion
KM, Morgenthien E, et al. Spectral-domain OCT-based pre-
valence and progression of macular atrophy in the HARBOR
study for neovascular age-related macular degeneration. Oph-
thalmology. 2020;127:523–32.
65. Xu L, Mrejen S, Jung JJ, Gallego-Pinazo R, Thompson D, Mar-
siglia M, et al. Geographic atrophy in patients receiving anti-
vascular endothelial growth factor for neovascular age-related
macular degeneration. Retina. 2015;35:176–86.
66. Baek J, Lee JH, Kim JY, Kim NH, Lee WK. Geographic atrophy
and activity of neovascularization in retinal angiomatous pro-
liferation. Investig Ophthalmol Vis Sci. 2016;57:1500–5.
67. Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ,
Guymer RH, et al. Long-term outcomes of treatment of neovas-
cular age-related macular degeneration: data from an observa-
tional study. Ophthalmology. 2015;122:1837–45.
68. Zarbin M, Tsuboi M, Hill LF, Stoilov I. Simulating an anti-
vascular endothelial growth factor switch in neovascular age-
related macular degeneration: a HARBOR subanalysis. Ophthal-
mology. 2019;126:849–55.
69. Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y,
Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-
and-extend regimens in exudative age-related macular degenera-
tion: 52- and 96-week findings from ALTAIR: a randomized
controlled trial. Adv Ther. 2020;37:1173–87.
70. Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF,
Freund KB. Outer retinal tubulation: a novel optical coherence
tomography finding. Arch Ophthalmol. 2009;127:1596–602.
71. Kashani AH, Keane PA, Dustin L, Walsh AC, Sadda SR.
Quantitative subanalysis of cystoid spaces and outer nuclear layer
using optical coherence tomography in age-related macular
degeneration. Investig Ophthalmol Vis Sci. 2009;50:3366–73.
72. Kim JH, Chang YS, Kim JW, Kim CG, Lee DW. Abrupt visual
loss during anti-vascular endothelial growth factor treatment for
type 3 neovascularization. Int J Ophthalmol. 2019;12:480–7.
73. Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes
with secondary loss of visual acuity receiving variable dosing
ranibizumab for neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol. 2011;249:1635–42.
74. Lai TT, Hsieh YT, Yang CM, Ho TC, Yang CH. Biomarkers of
optical coherence tomography in evaluating the treatment out-
comes of neovascular age-related macular degeneration: a real-
world study. Sci Rep. 2019;9:529.
75. Lee H, Ji B, Chung H, Kim HC. Correlation between optical
coherence tomographic hyperreflective foci and visual outcomes
after anti-VEGF treatment in neovascular age-related macular
degeneration and polypoidal choroidal vasculopathy. Retina.
2016;36:465–75.
76. Mrejen S, Jung JJ, Chen C, Patel SN, Gallego-Pinazo R, Yannuzzi
N, et al. Long-term visual outcomes for a treat and extend anti-
vascular endothelial growth factor regimen in eyes with neovas-
cular age-related macular degeneration. J Clin Med. 2015;4:
1380–402.
77. Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
Evaluation of injection frequency and visual acuity outcomes for
ranibizumab monotherapy in exudative age-related macular
degeneration. Ophthalmology. 2009;116:1740–7.
78. Unver YB, Yavuz GA, Bekiroglu N, Presti P, Li W, Sinclair SH.
Relationships between clinical measures of visual function and
anatomic changes associated with bevacizumab treatment for
choroidal neovascularization in age-related macular degeneration.
Eye. 2009;23:453–60.
79. Silva R, Cachulo ML, Fonseca P, Bernardes R, Nunes S,
Vilhena N, et al. Age-related macular degeneration and risk fac-
tors for the development of choroidal neovascularisation in the
fellow eye: A 3-year follow-up study. Ophthalmologica. 2011;
226:110–8.
80. Gianniou C, Dirani A, Jang L, Mantel I. Refractory intraretinal or
subretinal fluid in neovascular age-related macular degeneration
treated with intravitreal ranizubimab: functional and structural
outcome. Retina. 2015;35:1195–201.
81. Lin T, Dans KC, Muftuoglu IK, Meshi A, Amador-Patarroyo MJ,
Cheng L, et al. Factors associated with extended remission in
neovascular age-related macular degeneration on pro re nata
treatment protocol. Br J Ophthalmol. 2020;104:58–63.
82. CATT Research Group, Martin DF, Maguire MG, Ying GS,
Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for
neovascular age-related macular degeneration. N Engl J Med.
2011;364:1897–908.
83. Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA,
Li Z, et al. Twenty-four-month efficacy and safety of 0.5 mg
or 2.0 mg ranibizumab in patients with subfoveal neovascular
age-related macular degeneration. Ophthalmology. 2014;121:
2181–92.
84. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-
Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for
neovascular age-related macular degeneration: results from the
GEFAL noninferiority randomized trial. Ophthalmology.
2013;120:2300–9.
Fluid as a critical biomarker in neovascular age-related macular degeneration management
